Diabetes Medication Transition



A programme by WellSouth

Last updated 24/01/2024

Intended Purpose

This programme is to support transitioning Māori, Pasifika, and CSC (community services card) holder patients with diabetes onto Empagliflozin, Dulaglutide, and Liraglutide, until 30 June 2024.

Eligibility—Initial Consult

The patient must have type II diabetes and either be:

- Māori, or
- · Pasifika, or
- CSC holder

AND eligible to be transitioned onto one of: Empagliflozin, Dulaglutide, or Liraglutide.

Eligibility—Follow-up Consult

- Maori, or
- Pasifika, or
- CSC holder

AND recently transitioned onto one of: Empagliflozin, Dulaglutide, or Liraglutide.

Key Information

- A thalamus Dashboard to support identifying eligible patients can be found <u>here</u>.
- The initial consultation is funded at \$60 +GST and should facilitate a GP/NP consult with the patient to determine if the new medication is clinically appropriate.
- The follow-up package is funded at \$40 + GST and should facilitate a clinician checking how the patient is tolerating the new medication, and if other medications need adjusted.

Claiming

Claiming is via the WellSouth PHN portal.



Service codes for your PMS

Please set these up prior to using the programme.

Code	Amount (incl. GST)	Description
WPG001	\$69.00	Diabetes medication transition - Initial consult
WPG002	\$46.00	Diabetes medication transition - follow-up consult

Payment Rates

\$ 60.00 + GST Initial consult

\$40.00 + GST Follow up consult

No simultaneous claim is to be made against any other funding stream for this service.

Can a co-payment be charged?

No co-payment can be charged (including issuing prescriptions if required).

When does the claim need to be completed?

Claiming must be completed within 2 months of treatment.

If your PMS is aligned to the WellSouth Clinical BCTIs, please contact <u>practicenetwork@wellsouth.org.nz</u> with your new Account Internal ID.